Here you will find all the research and views on CIPLA that we post on Equitymaster. Use the tools to customize the results to suit your preference!
Here's an analysis of the annual report of CIPLA for 2023-24. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
Check out CIPLA fact sheet and CIPLA financial results online at Equitymaster.
Check out latest CIPLA Quarterly Results online at Equitymaster.
CIPLA: Get the latest CIPLA Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.
These companies have issued bonus shares the most times. Do you own any?
These debt-free giants offer valuable insights into what it takes to succeed without relying on borrowed money.
Active pharmaceutical ingredients (APIs) are the key ingredients in medicines. Here are the top Indian leading manufacturers of API.
The Indian pharmaceutical industry is on its journey to become US$ 130 billion by 2030, and this company stands to benefit the most.
Multiple technical factors indicate that investors should avoid pharma stocks in the current market. More details inside...
One of the best pharma stocks in India, Cipla is starting to show signs of downtrend after a decent rally in early 2023. What next?
With Covid cases rising in China, stocks specific to covid are reacting both ways. Find out the biggest beneficiaries and the ones to get most affected.
Pharma stocks are in focus amid renewed fears of Covid outbreaks and have rallied between 5-15% in the past couple of days.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
As the new variant of Covid-19 emerges, keep an eye on these stocks.
These companies are likely to benefit the most from Covid-19 vaccines.
The stock fell 3.5% even as the company reported numbers higher than analysts' expectations.
The first batch of Roche's antibody cocktail has been launched in India, with the second batch to be made available by mid-June.